Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 25 June 2014 | By Alexander Gaffney, RAC,
Regulators with the US Food and Drug Administration (FDA) have released a second, substantially more complete guidance document indicating how its Global Unique Device Identification Database (GUDID), an integral part of the agency's pending oversight of the Unique Device Identification (UDI) system, works.
Under FDA's UDI regulation, medical device manufacturers will soon have to start affixing device identifiers and production identifiers to most devices. While that information is somewhat useful on its own, its real potential will be unlocked when the information is tracked using the GUDID, which is set to act as a repository of information on the devices. For example, a doctor might scan a device code before using a device on a patient, allowing the doctor to see if the device has been recalled, how many devices are supposed to be in the package, whether the device has been discontinued, and to confirm that they have the right device in hand.
For more on GUDID, please see Focus' 10 June 2014 story, FDA Releases Final, Slimmed-Down GUDID Guidance, Leaving Many Details for Later.
FDA first released a draft guidance document on GUDID in September 2013, and on 10 June 2014 released a "final" version of that guidance. But as it explained in its Federal Register announcement, "final" was something of a misnomer.
As explained by Regulatory Focus at the time, FDA indicated that the guidance was not yet complete, and at least 14 sections of the guidance would be finalized "separately."
"In order to provide labelers access to the latest information as soon as it is available, and address sections that received the most comments and questions, sections of this document are finalized; sections still in draft state are noted and will be finalized at a later time," FDA explained. "A future document" will address those now-empty sections, FDA confirmed in its Federal Register posting on the guidance.
As Focus explained at the time, FDA did make some changes to the draft guidance, such as adding substantial amounts of detail on the use of GUDID accounts and the classification of devices using the Global Medical Device Nomenclature (GMDN).
Now FDA is out with those "separate" additions to the guidance, Global Unique Device Identification Database (GUDID), and has released an updated and unified final guidance document on the GUDID system.
The detailed and extensive guidance, which weighs in at 42 pages in length, provides much of the technical "how-to" of the GUDID system, such as the role of each entity within the GUDID system, how to obtain a GUDID account, how to register a device and packages, and how to edit submissions.
Global Unique Device Identification Database (GUDID)
Tags: GUDID, UDI, GMDN, Global Medical Device Nomenclature, Unique Device Identification, Global Unique Device Identification Database
Regulatory Focus newsletters
All the biggest regulatory news and happenings.